Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years

Authors not listed

Alachua Government Services, Inc. · 2009

Abstract

The purpose of this study is to assess the safety and immunogenicity (i.e. primary immune response, immunogenicity of two different doses, antibody persistence 360 days after the first vaccination, immune response to a heterologous booster given on Day 360) of a Vero cell-derived whole virus H5N1 influenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-25 MST

Cite this

APA
Anonymous. (2009). A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years. <em>Alachua Government Services, Inc.</em>. https://clinicaltrials.gov/study/NCT01052402
Vancouver
Anonymous. A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years. Alachua Government Services, Inc.. 2009.
BibTeX
@misc{anon2009APhase, title = {A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years}, author = {Anonymous}, journal = {Alachua Government Services, Inc.}, year = {2009}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings